Abstract
Although interventional regimens have rightly become the gold standard treatment for the control of haemoptysis, medication, especially vasoconstrictor medication, is still routinely administered in the clinic. The vasoconstrictor posterior pituitary hormone is the most commonly prescribed drug for the management of haemoptysis in China. However, vasoconstrictor therapy has various adverse effects, some of which may be severe, and is ineffective in a few patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
